ZA201807105B - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide - Google Patents
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideInfo
- Publication number
- ZA201807105B ZA201807105B ZA2018/07105A ZA201807105A ZA201807105B ZA 201807105 B ZA201807105 B ZA 201807105B ZA 2018/07105 A ZA2018/07105 A ZA 2018/07105A ZA 201807105 A ZA201807105 A ZA 201807105A ZA 201807105 B ZA201807105 B ZA 201807105B
- Authority
- ZA
- South Africa
- Prior art keywords
- difluoroacetamide
- dioxopiperidin
- oxoisoindolin
- chlorophenyl
- methyl
- Prior art date
Links
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 title 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 title 1
- 201000005787 hematologic cancer Diseases 0.000 title 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346344P | 2016-06-06 | 2016-06-06 | |
| PCT/US2017/035892 WO2017214014A1 (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201807105B true ZA201807105B (en) | 2020-01-29 |
Family
ID=60482040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/07105A ZA201807105B (en) | 2016-06-06 | 2018-10-24 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10245258B2 (OSRAM) |
| EP (1) | EP3463358A4 (OSRAM) |
| JP (1) | JP7163281B2 (OSRAM) |
| KR (1) | KR20190015300A (OSRAM) |
| CN (2) | CN109414436A (OSRAM) |
| AU (2) | AU2017278114B2 (OSRAM) |
| BR (1) | BR112018075206A2 (OSRAM) |
| CA (1) | CA3026396A1 (OSRAM) |
| CL (1) | CL2018003499A1 (OSRAM) |
| EA (1) | EA201892746A1 (OSRAM) |
| IL (1) | IL262565B (OSRAM) |
| MX (1) | MX388717B (OSRAM) |
| SG (1) | SG11201809501PA (OSRAM) |
| WO (1) | WO2017214014A1 (OSRAM) |
| ZA (1) | ZA201807105B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| MX390772B (es) * | 2016-01-08 | 2025-03-21 | Celgene Corp | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. |
| US11535603B1 (en) | 2016-09-30 | 2022-12-27 | Deuterx, Llc | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same |
| PL3689868T3 (pl) | 2016-12-01 | 2024-03-11 | Arvinas Operations, Inc. | Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych |
| CA3125189A1 (en) * | 2018-12-31 | 2020-07-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide |
| MX2022002415A (es) | 2019-08-26 | 2022-03-22 | Arvinas Operations Inc | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
| CA3154923A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| WO2021091946A1 (en) | 2019-11-05 | 2021-05-14 | Celgene Corporation | Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide |
| CN114761004A (zh) | 2019-12-06 | 2022-07-15 | 细胞基因公司 | 用于制备2-(4-氯苯基)-n-((2-(2，6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2，2-二氟乙酰胺的方法 |
| BR112022018515A2 (pt) * | 2020-03-16 | 2022-11-16 | Celgene Corp | Terapia de combinação para leucemia mieloide aguda |
| BR112023004656A2 (pt) * | 2020-09-14 | 2023-05-09 | Arvinas Operations Inc | Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio |
| MX2023003114A (es) | 2020-09-23 | 2023-03-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon. |
| KR20240066906A (ko) * | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050044655A (ko) * | 2001-12-03 | 2005-05-12 | 노바세아, 인크. | 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물 |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20090175869A1 (en) | 2007-05-31 | 2009-07-09 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| ATE505194T1 (de) | 2009-05-20 | 2011-04-15 | Hybrigenics Sa | Neue therapeutische verwendungen von inecalcitol |
| EA201490911A1 (ru) | 2011-11-01 | 2014-09-30 | Селджин Корпорейшн | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина |
| US20160303158A1 (en) * | 2013-12-05 | 2016-10-20 | Hoffmann-La Roche Inc. | Novel combination treatment for acute myeloid leukemia (aml) |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| US10189808B2 (en) | 2016-01-08 | 2019-01-29 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| AR107321A1 (es) | 2016-01-08 | 2018-04-18 | Celgene Corp | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos |
| CA3010797C (en) | 2016-01-08 | 2024-01-02 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2017
- 2017-06-05 KR KR1020187035780A patent/KR20190015300A/ko not_active Ceased
- 2017-06-05 CN CN201780035323.6A patent/CN109414436A/zh active Pending
- 2017-06-05 CA CA3026396A patent/CA3026396A1/en active Pending
- 2017-06-05 IL IL262565A patent/IL262565B/en unknown
- 2017-06-05 MX MX2018015120A patent/MX388717B/es unknown
- 2017-06-05 EA EA201892746A patent/EA201892746A1/ru unknown
- 2017-06-05 SG SG11201809501PA patent/SG11201809501PA/en unknown
- 2017-06-05 WO PCT/US2017/035892 patent/WO2017214014A1/en not_active Ceased
- 2017-06-05 CN CN202211003162.1A patent/CN115282149A/zh active Pending
- 2017-06-05 US US15/614,434 patent/US10245258B2/en active Active
- 2017-06-05 EP EP17810774.4A patent/EP3463358A4/en not_active Withdrawn
- 2017-06-05 BR BR112018075206-1A patent/BR112018075206A2/pt not_active Application Discontinuation
- 2017-06-05 JP JP2019516086A patent/JP7163281B2/ja active Active
- 2017-06-05 AU AU2017278114A patent/AU2017278114B2/en active Active
-
2018
- 2018-10-24 ZA ZA2018/07105A patent/ZA201807105B/en unknown
- 2018-12-06 CL CL2018003499A patent/CL2018003499A1/es unknown
-
2019
- 2019-02-13 US US16/275,234 patent/US20190175573A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,267 patent/US11590117B2/en active Active
-
2023
- 2023-01-25 US US18/101,499 patent/US20230158009A1/en not_active Abandoned
- 2023-04-06 AU AU2023202159A patent/AU2023202159A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017278114A1 (en) | 2018-11-29 |
| US20210154182A1 (en) | 2021-05-27 |
| BR112018075206A2 (pt) | 2019-03-19 |
| CN109414436A (zh) | 2019-03-01 |
| US20230158009A1 (en) | 2023-05-25 |
| IL262565A (en) | 2018-12-31 |
| MX388717B (es) | 2025-03-20 |
| AU2017278114B2 (en) | 2023-01-12 |
| IL262565B (en) | 2022-08-01 |
| US10245258B2 (en) | 2019-04-02 |
| MX2018015120A (es) | 2019-04-15 |
| WO2017214014A1 (en) | 2017-12-14 |
| KR20190015300A (ko) | 2019-02-13 |
| AU2023202159A1 (en) | 2023-05-04 |
| CL2018003499A1 (es) | 2019-03-15 |
| SG11201809501PA (en) | 2018-12-28 |
| EP3463358A1 (en) | 2019-04-10 |
| EP3463358A4 (en) | 2020-07-22 |
| US20190175573A1 (en) | 2019-06-13 |
| CA3026396A1 (en) | 2017-12-14 |
| JP7163281B2 (ja) | 2022-10-31 |
| US20170348298A1 (en) | 2017-12-07 |
| CN115282149A (zh) | 2022-11-04 |
| EA201892746A1 (ru) | 2019-06-28 |
| US11590117B2 (en) | 2023-02-28 |
| JP2019517587A (ja) | 2019-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807105B (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| ZA201804482B (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SI3644999T1 (sl) | Sestavki in postopki uporabe 2-(4-klorofenil)-N-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoroacetamida | |
| KR102060995B9 (ko) | 제어가능한 외부 디바이스들을 관리하기 위한 사용자 인터페이스 | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| IL257282B (en) | Compounds 2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidine | |
| PL3395818T3 (pl) | 2-(morfolin-4-ylo)-1,7-naftyrydyny | |
| PL3331363T3 (pl) | Nowe zastosowania 2-(2,4-dichlorofenylo)metylo-4,4-dimetylo-3-izoksazolidonu jako herbicydu dolistnego | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| EP3486926A4 (en) | COMPOSED SMOOTHING INDUCTOR AND SMOOTHING CIRCUIT | |
| IL284509A (en) | Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide | |
| GB2550399B (en) | A novel form of sulfentrazone, a process for its preparation and use the same | |
| EP4054578A4 (en) | COMBINATION THERAPY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDINE-3-YL)-1-OXOISOINDOLINE-5-YL) METHYL)-2,2-DIFLUOROACETAMIDE | |
| EP3442618A4 (en) | LOADING DISPOSABLE ARTICLES | |
| FI20165467A7 (fi) | Menetelmä käyttäjän lääkityksen hallinnoimiseksi | |
| IL255208A0 (en) | Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-3,1-thiazol-4-yl]methyl}sulfanyl)-5,3-dicyano-6-(pyrrolidine-1- yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alanilate monohydrochloride | |
| EP3485921A4 (en) | ADHESION PREVENTING COMPOSITION | |
| IL265893A (en) | Crystal forms of 4-(2-((r1(2r,-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-n-methylpicolinamide | |
| HK40006235A (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| PL3274339T3 (pl) | Sposób wytwarzania chlorowodorków 2- (homo)-piperazyno-1,3-benzotiazyn-4-onu | |
| PL3105243T3 (pl) | Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie | |
| EP3441382A4 (en) | OXASÄUREVERBINDUNG | |
| HK40078208A (en) | Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide | |
| UA34481S (uk) | Сережки «зустріч витонченості» | |
| UA32691S (uk) | Брошка «о.w. grant» |